High-dose vitamin D3 in adults with pulmonary tuberculosis: a double-blind randomized controlled trial.

ABSTRACT:

Background

Tuberculosis, including multidrug-resistant tuberculosis (MDR-TB), is a major global health problem. Individuals with tuberculosis disease commonly exhibit vitamin D deficiency, which may adversely affect immunity and the response to therapy.

Objective

We determined whether adjunctive high-dose vitamin D3 supplementation improves outcomes in individuals with pulmonary tuberculosis disease.

Design

The study was a double-blind, randomized, placebo-controlled, intent-to-treat trial in 199 individuals with pulmonary tuberculosis disease in Tbilisi, Georgia. Subjects were randomly assigned to receive oral vitamin D3 [50,000 IUs (1.25 mg) thrice weekly for 8 wk and 50,000 IU every other week for 8 wk] or a placebo concomitant with standard first-line antitubercul

SUBMITTER: Tukvadze N 

PROVIDER: S-EPMC4625591 | biostudies-literature | 2015 Nov

REPOSITORIES: biostudies-literature